ʻO Apixaban

ʻO ka wehewehe pōkole:

Ka inoa o ka API Hōʻike Hōʻike US DMF EU DMF CEP
ʻO Apixaban VTE I-Hale


Huahana Huahana

Huahana Huahana

NUI HUA

Kāpae

ʻO Apixaban kahi mea koho nui a hiki ke hoʻololi i ka Factor Xa me nā helu Ki o 0.08 nM a me 0.17 nM i ke kanaka a me ka rabbit, i kēlā me kēia [1].

ʻO Factor X, ʻike ʻia hoʻi e ka eponym Stuart–Prower factor, he enzyme o ka coagulation cascade. Hoʻohana ʻia ka Factor X, ma ka hydrolysis, i ka helu Xa e nā mea ʻelua IX. ʻO ka Factor Xa ke ʻano hana o ka coagulation factorthrombokinase. Hiki i ka Inhibiting Factor Xa ke hāʻawi i kahi ala ʻē aʻe no ka anticoagulation. He mau anticoagulants kaulana ka Direct Xa inhibitors [2].

In vitro: Ua hōʻike ʻo Apixabanhas i kahi kiʻekiʻe o ka potency, selectivity, a me ka pono ma ka Factor Xa me Ki o 0.08 nM a me 0.17 nM no Human Factor Xa a me Rabbit Factor Xa, kēlā me kēia [1]. Ua hoʻolōʻihi ʻia ʻo Apixaban i nā manawa clotting o ka plasma kanaka maʻamau me nā manaʻo (EC2x) o 3.6, 0.37, 7.4 a me 0.4 μM, i koi ʻia e pālua i ka manawa prothrombin (PT), ka manawa prothrombin i hoʻololi ʻia (mPT), ka manawa thromboplastin ʻāpana. APTT) a me HepTest. Ma waho aʻe, ua hōʻike ʻo Apixaban i ka ikaika kiʻekiʻe loa i ka plasma kanaka a me ka rabbit plasma, akā ʻoi aku ka liʻiliʻi o ka ʻiole a me ka plasma ʻīlio ma ka PT a me ka APTT assays [3].

In vivo: Ua hōʻike ʻo Apixaban i nā pharmacokinetics maikaʻi loa me ka haʻahaʻa haʻahaʻa loa (Cl: 0.02 L kg-1h-1), a me ka haʻahaʻa haʻahaʻa o ka hāʻawi ʻana (Vdss: 0.2 L/kg) i ka ʻīlio. Ma waho aʻe, ua hōʻike pū ʻo Apixaban i ka hapalua o ke ola me T1 / 2 o 5.8 mau hola a me ka bioavailability waha maikaʻi (F: 58%) [1]. I ka arteriovenous-shunt thrombosis (AVST), venous thrombosis (VT) a me electrically mediated carotid arterial thrombosis (ECAT), ua hoʻopuka ʻo Apixaban i nā hopena antithrombotic me EC50 o 270 nM, 110 nM a me 70 nM ma ke ʻano i hilinaʻi ʻia. ]. Ua kāohi nui ʻo Apixaban i ka hana Xa me kahi IC50 o 0.22 μM i ka rabbit ex vivo [4]. I loko o ka chimpanzee, ua hōʻike pū ʻo Apixaban i ka puʻupuʻu liʻiliʻi o ka hāʻawi ʻana (Vdss: 0.17 L kg-1), ka hoʻomaʻemaʻe ʻōnaehana haʻahaʻa (Cl: 0.018 L kg-1h-1), a me ka bioavailability waha maikaʻi (F: 59%) [5].

Kuhikuhi:
Pinto DJP, Orwat MJ, Koch S, a me al. ʻIke ʻia o 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl) phenyl) -4, 5, 6, 7-tetrahydro-1 H-pyrazolo [3, 4- c] pyridine-3-carboxamide (Apixaban, BMS-562247), he ikaika loa, koho, pono, a hiki i ka waha. mea hoʻopaneʻe o ke koko coagulation factor Xa[J]. Journal of medicinal chemistry, 2007, 50(22): 5339-5356.
ʻO Sidhu P S. ʻO nā mea hōʻemi pololei Xa ma ke ʻano he Anticoagulants [J].
Wong PC, Crain EJ, Xin B, a me al. ʻO Apixaban, he mea hoʻopaneʻe Xa o ka waha, pololei a koho nui loa: in vitro, antithrombotic and antihemostaticstudies [J]. Journal of Thrombosis and Haemostasis, 2008, 6(5): 820-829.
Zhang D, He K, Raghavan N, et al. Metabolism, pharmacokinetics a me pharmacodynamics o ka mea Xa inhibitor apixaban i loko o ka lapiti [J]. Nūpepa o ka thrombosis a me ka thrombolysis, 2010, 29 (1): 70-80.
He K, Luettgen JM, Zhang D, a me al. ʻO nā pharmacokinetics preclinical a me nā lāʻau lapaʻau o apixaban, kahi mea hoʻopaʻapaʻa ikaika a koho Xa [J]. ʻO ka nūpepa ʻEulopa o ka metabolism lāʻau a me nā pharmacokinetics, 2011, 36 (3): 129-139.

ʻO Apixaban kahi mea koho nui a hiki ke hoʻololi i ka Factor Xa me nā helu Ki o 0.08 nM a me 0.17 nM i ke kanaka a me ka rabbit, i kēlā me kēia [1].

ʻO Factor X, ʻike ʻia hoʻi e ka eponym Stuart–Prower factor, he enzyme o ka coagulation cascade. Hoʻohana ʻia ka Factor X, ma ka hydrolysis, i ka helu Xa e nā mea ʻelua IX. ʻO ka Factor Xa ke ʻano hana o ka coagulation factorthrombokinase. Hiki i ka Inhibiting Factor Xa ke hāʻawi i kahi ala ʻē aʻe no ka anticoagulation. He mau anticoagulants kaulana ka Direct Xa inhibitors [2].

In vitro: Ua hōʻike ʻo Apixabanhas i kahi kiʻekiʻe o ka potency, selectivity, a me ka pono ma ka Factor Xa me Ki o 0.08 nM a me 0.17 nM no Human Factor Xa a me Rabbit Factor Xa, kēlā me kēia [1]. Ua hoʻolōʻihi ʻia ʻo Apixaban i nā manawa clotting o ka plasma kanaka maʻamau me nā manaʻo (EC2x) o 3.6, 0.37, 7.4 a me 0.4 μM, i koi ʻia e pālua i ka manawa prothrombin (PT), ka manawa prothrombin i hoʻololi ʻia (mPT), ka manawa thromboplastin ʻāpana. APTT) a me HepTest. Ma waho aʻe, ua hōʻike ʻo Apixaban i ka ikaika kiʻekiʻe loa i ka plasma kanaka a me ka rabbit plasma, akā ʻoi aku ka liʻiliʻi o ka ʻiole a me ka plasma ʻīlio ma ka PT a me ka APTT assays [3].

In vivo: Ua hōʻike ʻo Apixaban i nā pharmacokinetics maikaʻi loa me ka haʻahaʻa haʻahaʻa loa (Cl: 0.02 L kg-1h-1), a me ka haʻahaʻa haʻahaʻa o ka hāʻawi ʻana (Vdss: 0.2 L/kg) i ka ʻīlio. Ma waho aʻe, ua hōʻike pū ʻo Apixaban i ka hapalua o ke ola me T1 / 2 o 5.8 mau hola a me ka bioavailability waha maikaʻi (F: 58%) [1]. I ka arteriovenous-shunt thrombosis (AVST), venous thrombosis (VT) a me electrically mediated carotid arterial thrombosis (ECAT), ua hoʻopuka ʻo Apixaban i nā hopena antithrombotic me EC50 o 270 nM, 110 nM a me 70 nM ma ke ʻano i hilinaʻi ʻia. ]. Ua kāohi nui ʻo Apixaban i ka hana Xa me kahi IC50 o 0.22 μM i ka rabbit ex vivo [4]. I loko o ka chimpanzee, ua hōʻike pū ʻo Apixaban i ka puʻupuʻu liʻiliʻi o ka hāʻawi ʻana (Vdss: 0.17 L kg-1), ka hoʻomaʻemaʻe ʻōnaehana haʻahaʻa (Cl: 0.018 L kg-1h-1), a me ka bioavailability waha maikaʻi (F: 59%) [5].

Kuhikuhi:
Pinto DJP, Orwat MJ, Koch S, a me al. ʻIke ʻia o 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl) phenyl) -4, 5, 6, 7-tetrahydro-1 H-pyrazolo [3, 4- c] pyridine-3-carboxamide (Apixaban, BMS-562247), he ikaika loa, koho, pono, a hiki i ka waha. mea hoʻopaneʻe o ke koko coagulation factor Xa[J]. Journal of medicinal chemistry, 2007, 50(22): 5339-5356.
ʻO Sidhu P S. ʻO nā mea hōʻemi pololei Xa ma ke ʻano he Anticoagulants [J].
Wong PC, Crain EJ, Xin B, a me al. ʻO Apixaban, he mea hoʻopaneʻe Xa o ka waha, pololei a koho nui loa: in vitro, antithrombotic and antihemostaticstudies [J]. Journal of Thrombosis and Haemostasis, 2008, 6(5): 820-829.
Zhang D, He K, Raghavan N, et al. Metabolism, pharmacokinetics a me pharmacodynamics o ka mea Xa inhibitor apixaban i loko o ka lapiti [J]. Nūpepa o ka thrombosis a me ka thrombolysis, 2010, 29 (1): 70-80.
He K, Luettgen JM, Zhang D, a me al. ʻO nā pharmacokinetics preclinical a me nā lāʻau lapaʻau o apixaban, kahi mea hoʻopaʻapaʻa ikaika a koho Xa [J]. ʻO ka nūpepa ʻEulopa o ka metabolism lāʻau a me nā pharmacokinetics, 2011, 36 (3): 129-139.

ʻO ke kinona

ʻO Apixaban

HOOLAHA ANOAI

Hoʻoponopono maikaʻi1

Manaʻo18Nā papahana Loiloi Kūlike Kūlike i ʻae ʻia4, a6apono ʻia nā papahana.

Hoʻoponopono maikaʻi2

Ua hoʻokumu ka ʻōnaehana hoʻokele maikaʻi honua kiʻekiʻe i ke kumu kūʻai.

Hoʻoponopono maikaʻi3

Holo ka nānā ʻana i ka maikaʻi ma ke ola holoʻokoʻa o ka huahana e hōʻoia i ka maikaʻi a me ka hopena therapeutic.

Hoʻoponopono maikaʻi4

Kākoʻo ka hui ʻoihana Regulatory Affairs i nā koi maikaʻi i ka wā o ke noi a me ke kākau inoa ʻana.

HOOLAHA HANA

cpf5
cpf6

Kolea Countec Bottled Packaging Line

cpf7
cpf8

ʻO Taiwan CVC Bottled Packaging Line

cpf9
cpf10

Italia CAM Board Packaging Line

cpf11

Mekini Fette Compacting German

cpf12

ʻO Iapana Viswill Tablet ʻIke

cpf14-1

Keena Mana o DCS

HOA

Ka launa pū ʻana o ka honua
Ka launa pū ʻana o ka honua
ʻO ka launa pū ʻana o ka home
ʻO ka launa pū ʻana o ka home

  • Mua:
  • Aʻe:

  • E kākau i kāu leka ma aneʻi a hoʻouna mai iā mākou

    Māhele huahana